De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as an Anti-Alzheimer's.
There are over 44 million persons who suffer with Alzheimer's disease (AD) worldwide. Presently only symptomatic treatments are available for AD but there is no existence of cure. The aim of this study is to evaluate the anti-Alzheimer potential of designed AChEI analogues using computer simulation docking studies. AChEIs are the most potential standards for treatment of AD, because they have proven efficacy and among the all therapies donepezil used to treat mild-moderate-severe AD. It possesses lowest adverse effects than any other AChEIs and only once-daily dosing is required for the treatment of AD. Therefore donepezil is recognized as a significant prototype for design and development of new drug molecule by using its structural features, optimizing its properties, and improving its activity with the help of CADD approaches. This study also provides an idea about drug-receptor interactions by which we can find a more efficacious molecule with more possibilities for becoming a new drug candidate. In this study the Inhibitory potential of the design compounds on acetylcholinesterase enzyme has been evaluated. Docking studies has been performed which further analyzed by in-silico pharmacokinetic evaluation through pharmacopredicta after that Interaction modes with enzyme active sites were determined. Docking studies revealed that there is a strong interaction between the active sites of AChE enzyme and analyzed compounds. Finally 26 compounds have been indicates better inhibitory activity on AChE enzyme and all the screening parameters have also been satisfied by all 26 compounds.